<p>在過去的 7 天裏，美國市場下跌了 2.3%，但在過去一年中仍上漲了 13%，預計年收益增長將達到 16%。在這種背景下，識別高增長科技股需要尋找那些展現出強大創新能力和適應能力的公司，使其在波動的市場環境中佔據有利位置。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.02%</td>
<td>31.25%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.20%</td>
<td>27.96%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>30.23%</td>
<td>46.19%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ondas</td>
<td>35.55%</td>
<td>69.51%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.90%</td>
<td>48.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.76%</td>
<td>155.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>12.08%</td>
<td>99.98%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 73 只股票的完整列表。</p>
<p>讓我們深入探討篩選器中的一些優質選擇。</p>
<h2>Protagonist Therapeutics (PTGX)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Protagonist Therapeutics, Inc. 是一家總部位於美國的發現與開發公司，市值為 62.9 億美元。</p>
<p><strong>運營：</strong> Protagonist Therapeutics 專注於生物技術，從該領域產生的收入為 4602 萬美元。</p>
<p>Protagonist Therapeutics 預計將在三年內從虧損轉向盈利，年利潤增長預期為 40.85%。這一轉變得益於預計年收入增長 23.6%，超過美國市場平均 10.4% 的水平。最近，FDA 對 rusfertide 和 ICOTYDE(TM) 的批准突顯了其在應對複雜醫療條件（如真性紅細胞增多症和斑塊性銀屑病）方面的創新優勢，可能設定新的行業標準並增強其市場地位。儘管在其第四季度財報中記錄了 4438 萬美元的淨虧損，但這些戰略產品的進展可能會催化轉機，提升其在生物技術領域的競爭地位。</p>
<ul>
<li>在本健康報告中解鎖我們對 Protagonist Therapeutics 股票分析的全面見解。</li>
<li>在我們的歷史部分探索歷史數據，以跟蹤 Protagonist Therapeutics 的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 3 月 PTGX 的收益和收入增長</p>
<h2>Everpure (PSTG)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Everpure, Inc. 專注於全球數據存儲和管理技術、產品及服務，市值約為 212.8 億美元。</p>
<p><strong>運營：</strong> Everpure, Inc. 從其計算機存儲設備部門獲得約 36.6 億美元的收入，專注於在美國和國際上提供數據存儲和管理解決方案。</p>
<p>Everpure 最近的戰略舉措強調了其增強人工智能基礎設施能力的承諾，這對維持在科技行業的競爭力至關重要。Everpure 推出了 Evergreen//One for FlashBlade//EXA 和即將推出的 Everpure Data Stream 測試版，旨在減少企業人工智能項目的複雜性和成本。這些創新旨在簡化從數據攝取到推理的數據處理，通過自動化數據移動顯著加快結果時間。這種方法不僅簡化了人工智能部署的操作方面，還確保在大規模應用中始終滿足高性能標準，FlashBlade//EXA 在 SPECstorage Solution 2020 和 MLPerf 測試中的創紀錄基準分數就是明證。通過與 NVIDIA 的模塊化 STX 參考架構對齊，Everpure 準備滿足下一代人工智能工廠日益增長的需求，確保其解決方案始終處於技術進步的前沿，同時支持可持續增長。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解 Everpure 的潛力。</li>
<li>通過我們的詳細歷史表現報告評估 Everpure 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 3 月 PSTG 的收益和收入增長</p>
<h2>Clear Secure (YOU)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Clear Secure, Inc. 在美國主要運營一個安全身份平台，品牌名稱為 CLEAR，市值約為 71.3 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其安全生物識別身份驗證部門產生收入，該部門貢獻了 9.0078 億美元。</p>
<p>Clear Secure 最近增強其身份驗證解決方案，展現出在高需求科技領域的強勁增長和創新。公司年收入增長 12%，預計盈利將上升 23.7%，其戰略重點顯而易見。他們最近與 Ochsner Health 合作，在醫療工作流程中部署 CLEAR1，突顯了他們將先進技術無縫集成到日常運營中的承諾。這一舉措不僅提升了安全性，還簡化了患者和員工的訪問，使 Clear Secure 在醫療領域的數字身份解決方案中處於領先地位——這一領域正處於技術顛覆的邊緣。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Clear Secure 的動態。</li>
<li>通過查看我們的歷史報告瞭解 Clear Secure 的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown"/></p>
<p>YOU 收入和支出明細截至 2026 年 3 月</p>
<h2>接下來該怎麼辦？</h2>
<ul>
<li>在這裏發現 73 只美國高增長科技和人工智能股票的完整陣容。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>準備探索其他投資風格嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

標普醫療保健服務 ETF - SPDR

PSTG

基因改革 ETF - ARK

<p>美國市場在過去一週下跌了 2.3%，但在過去一年中仍上漲了 13%，預計年均盈利增長為 16%。主要的高增長科技股票包括 Protagonist Therapeutics、Everpure 和 Clear Secure，這些公司都顯示出強勁的收入和盈利增長。Protagonist 預計將實現盈利，年利潤增長率為 40.85%，而 Everpure 則專注於增強人工智能基礎設施。Clear Secure 在身份驗證方面進行創新，預計收入增長 12%，盈利增長 23.7%。投資者可以探索 73 只高增長科技股票的名單，以尋找潛在機會</p>

<p>Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability, positioning themselves well amidst fluctuating market conditions.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場下跌了 2.3%，但在過去一年中仍上漲了 13%，預計年收益增長將達到 16%。在這種背景下，識別高增長科技股需要尋找那些展現出強大創新能力和適應能力的公司，使其在波動的市場環境中佔據有利位置。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.02%</td>
<td>31.25%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.20%</td>
<td>27.96%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>30.23%</td>
<td>46.19%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ondas</td>
<td>35.55%</td>
<td>69.51%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.90%</td>
<td>48.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.76%</td>
<td>155.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>12.08%</td>
<td>99.98%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.02%</td>
<td>31.25%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.20%</td>
<td>27.96%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>30.23%</td>
<td>46.19%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ondas</td>
<td>35.55%</td>
<td>69.51%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.90%</td>
<td>48.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.76%</td>
<td>155.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>12.08%</td>
<td>99.98%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 73 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of from the screener.</p>
<div class="lb-trans"><p>讓我們深入探討篩選器中的一些優質選擇。</p>
</div><h2>Protagonist Therapeutics (PTGX)</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics (PTGX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Protagonist Therapeutics, Inc. is a discovery and development company based in the United States with a market capitalization of $6.29 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Protagonist Therapeutics, Inc. 是一家總部位於美國的發現與開發公司，市值為 62.9 億美元。</p>
</div><p><strong>Operations:</strong> Protagonist Therapeutics focuses on biotechnology, generating revenue of $46.02 million from this segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> Protagonist Therapeutics 專注於生物技術，從該領域產生的收入為 4602 萬美元。</p>
</div><p>Protagonist Therapeutics, poised for significant growth, is expected to transition from unprofitability to profitability within three years, with an anticipated annual profit growth of 40.85%. This shift is underscored by a robust revenue increase forecast at 23.6% annually, outpacing the US market's average of 10.4%. Recent FDA nods for rusfertide and ICOTYDE(TM) highlight its innovative edge in addressing complex medical conditions like polycythemia vera and plaque psoriasis, potentially setting new industry standards and bolstering its market position. Despite recent financial setbacks noted in its Q4 earnings report—where a net loss of $44.38 million was recorded—these strategic product advancements could catalyze a turnaround, enhancing its competitive stance in the biotech sector.</p>
<div class="lb-trans"><p>Protagonist Therapeutics 預計將在三年內從虧損轉向盈利，年利潤增長預期為 40.85%。這一轉變得益於預計年收入增長 23.6%，超過美國市場平均 10.4% 的水平。最近，FDA 對 rusfertide 和 ICOTYDE(TM) 的批准突顯了其在應對複雜醫療條件（如真性紅細胞增多症和斑塊性銀屑病）方面的創新優勢，可能設定新的行業標準並增強其市場地位。儘管在其第四季度財報中記錄了 4438 萬美元的淨虧損，但這些戰略產品的進展可能會催化轉機，提升其在生物技術領域的競爭地位。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Protagonist Therapeutics stock in this health report.</li>
<li>Explore historical data to track Protagonist Therapeutics' performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>在本健康報告中解鎖我們對 Protagonist Therapeutics 股票分析的全面見解。</li>
<li>在我們的歷史部分探索歷史數據，以跟蹤 Protagonist Therapeutics 的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth"/></p>
<p>PTGX Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月 PTGX 的收益和收入增長</p>
</div><h2>Everpure (PSTG)</h2>
<div class="lb-trans"><h2>Everpure (PSTG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Everpure, Inc. specializes in data storage and management technologies, products, and services globally with a market capitalization of approximately $21.28 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Everpure, Inc. 專注於全球數據存儲和管理技術、產品及服務，市值約為 212.8 億美元。</p>
</div><p><strong>Operations:</strong> With a revenue of approximately $3.66 billion from its Computer Storage Devices segment, Everpure, Inc. focuses on delivering data storage and management solutions both in the U.S. and internationally.</p>
<div class="lb-trans"><p><strong>運營：</strong> Everpure, Inc. 從其計算機存儲設備部門獲得約 36.6 億美元的收入，專注於在美國和國際上提供數據存儲和管理解決方案。</p>
</div><p>Everpure's recent strategic initiatives underscore its commitment to enhancing AI infrastructure capabilities, crucial for maintaining competitiveness in the tech sector. With a focus on reducing complexity and cost in enterprise AI projects, Everpure introduced Evergreen//One for FlashBlade//EXA and the upcoming beta of Everpure Data Stream. These innovations are designed to streamline data handling from ingestion to inference, significantly accelerating time-to-result by automating data movement. This approach not only simplifies the operational aspect of AI deployments but also ensures high-performance standards are met consistently across large-scale applications, evidenced by FlashBlade//EXA's record-setting benchmark scores in SPECstorage Solution 2020 and MLPerf tests. By aligning with NVIDIA's modular STX reference architecture, Everpure is poised to meet the escalating demands of next-generation AI factories, ensuring that their solutions remain at the forefront of technology advancements while supporting sustainable growth.</p>
<div class="lb-trans"><p>Everpure 最近的戰略舉措強調了其增強人工智能基礎設施能力的承諾，這對維持在科技行業的競爭力至關重要。Everpure 推出了 Evergreen//One for FlashBlade//EXA 和即將推出的 Everpure Data Stream 測試版，旨在減少企業人工智能項目的複雜性和成本。這些創新旨在簡化從數據攝取到推理的數據處理，通過自動化數據移動顯著加快結果時間。這種方法不僅簡化了人工智能部署的操作方面，還確保在大規模應用中始終滿足高性能標準，FlashBlade//EXA 在 SPECstorage Solution 2020 和 MLPerf 測試中的創紀錄基準分數就是明證。通過與 NVIDIA 的模塊化 STX 參考架構對齊，Everpure 準備滿足下一代人工智能工廠日益增長的需求，確保其解決方案始終處於技術進步的前沿，同時支持可持續增長。</p>
</div><ul>
<li>Take a closer look at Everpure's potential here in our health report.</li>
<li>Assess Everpure's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解 Everpure 的潛力。</li>
<li>通過我們的詳細歷史表現報告評估 Everpure 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth"/></p>
<p>PSTG Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月 PSTG 的收益和收入增長</p>
</div><h2>Clear Secure (YOU)</h2>
<div class="lb-trans"><h2>Clear Secure (YOU)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Clear Secure, Inc. operates a secure identity platform under the CLEAR brand name primarily in the United States, with a market cap of approximately $7.13 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Clear Secure, Inc. 在美國主要運營一個安全身份平台，品牌名稱為 CLEAR，市值約為 71.3 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its Secure Biometric Identity Verification segment, which contributed $900.78 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其安全生物識別身份驗證部門產生收入，該部門貢獻了 9.0078 億美元。</p>
</div><p>Clear Secure, recently enhancing its identity verification solutions, demonstrates robust growth and innovation in high-demand tech sectors. With a 12% annual revenue increase and an anticipated 23.7% rise in earnings, the company's strategic focus is evident. Their recent partnership with Ochsner Health to deploy CLEAR1 across healthcare workflows underscores their commitment to integrating advanced technology seamlessly into everyday operations. This initiative not only boosts security but also streamlines patient and employee access, positioning Clear Secure at the forefront of digital identity solutions in healthcare—a sector ripe for technological disruption.</p>
<div class="lb-trans"><p>Clear Secure 最近增強其身份驗證解決方案，展現出在高需求科技領域的強勁增長和創新。公司年收入增長 12%，預計盈利將上升 23.7%，其戰略重點顯而易見。他們最近與 Ochsner Health 合作，在醫療工作流程中部署 CLEAR1，突顯了他們將先進技術無縫集成到日常運營中的承諾。這一舉措不僅提升了安全性，還簡化了患者和員工的訪問，使 Clear Secure 在醫療領域的數字身份解決方案中處於領先地位——這一領域正處於技術顛覆的邊緣。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Clear Secure.</li>
<li>Understand Clear Secure's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Clear Secure 的動態。</li>
<li>通過查看我們的歷史報告瞭解 Clear Secure 的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown"/></p>
<p>YOU Revenue and Expenses Breakdown as at Mar 2026</p>
<div class="lb-trans"><p>YOU 收入和支出明細截至 2026 年 3 月</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該怎麼辦？</h2>
</div><ul>
<li>Discover the full array of 73 US High Growth Tech and AI Stocks right here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏發現 73 只美國高增長科技和人工智能股票的完整陣容。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Ready To Venture Into Other Investment Styles?</h2>
<div class="lb-trans"><h2>準備探索其他投資風格嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

當前值得關注的美國高增長科技股